Clinical Trial Update: Study to Evaluate the Safety and Immunogenicity of a Multivalent Pneumococcal Vaccine Given With Prevnar 13 in Healthy Infants [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and immunogenicity of a multivalent pneumococcal vaccine with Prevnar 13 in healthy infants; study terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pneumococcal Infections

Drugs mentioned

• Multivalent pneumococcal vaccine (investigational)
• Prevnar 13 (pneumococcal conjugate vaccine)

Snippet

Sponsor: Pfizer | Conditions: Pneumococcal Infections | Phase 2 | Status: TERMINATED | Results posted: 2021-11-30